GlassScriptPhysician profile
Kathy J Smith
NPI 1235135591
$5,990.11
in general payments reported to CMS, 2019-2025
35 companies · $868 in 2025
The $868 reported for 2025 was more than what 85% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $788 · 2022: $1,337 · 2023: $1,582 · 2024: $1,416 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,865.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $879.91 | 2023-2025 | Sunosi |
| Merck Sharp & Dohme LLC | $731.38 | 2021-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $503.24 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $471.50 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $420.34 | 2021-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $304.54 | 2022-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $279.27 | 2021-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $239.75 | 2021-2023 | |
| Amgen INC. | $239.00 | 2021-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $184.21 | 2021-2022 | |
| Genzyme Corporation | $167.98 | 2023 | |
| Jazz Pharmaceuticals INC. | $157.05 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $143.25 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $140.00 | 2021-2025 | Nexletol |
| Inspire Medical Systems, INC. | $133.67 | 2023 | Inspire |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $111.17 | 2022 | |
| Alnylam Pharmaceuticals INC. | $107.70 | 2021 | |
| Genentech USA, INC. | $106.57 | 2021 | |
| Abbvie INC. | $104.07 | 2023 | |
| Endologix LLC | $82.87 | 2021 | |
| Scpharmaceuticals INC. | $69.25 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.54 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $55.43 | 2021-2022 | |
| Lilly USA, LLC | $39.12 | 2025 | Zepbound, Mounjaro |
| Kiniksa Pharmaceuticals International, Plc | $36.07 | 2024 | Arcalyst |
| Novo Nordisk INC | $32.82 | 2025 | Wegovy |
| Edwards Lifesciences Corporation | $26.19 | 2022 | |
| Irhythm Technologies, INC. | $24.96 | 2024 | Zio Xt Patch, Zio Monitor |
| Daiichi Sankyo INC. | $24.91 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $23.91 | 2024 | Exparel, Iovera, Zilretta |
| Cvrx, INC. | $21.47 | 2024-2025 | Barostim Neo System |
| Biotronik INC. | $16.68 | 2024 | Biomonitor |
| Harmony Biosciences LLC | $16.46 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.86 | 2024 | Keveyis |
| Bayer Healthcare Pharmaceuticals INC. | $12.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.